Published in Mol Med on March 03, 2010
Celiac disease, inflammation and oxidative damage: a nutrigenetic approach. Nutrients (2012) 0.92
Peroxiredoxin 4, a novel circulating biomarker for oxidative stress and the risk of incident cardiovascular disease and all-cause mortality. J Am Heart Assoc (2012) 0.87
SNPs affecting serum metabolomic traits may regulate gene transcription and lipid accumulation in the liver. Metabolism (2012) 0.86
Gliadin peptides induce tissue transglutaminase activation and ER-stress through Ca2+ mobilization in Caco-2 cells. PLoS One (2012) 0.84
Differential proteomics of Helicobacter pylori associated with autoimmune atrophic gastritis. Mol Med (2014) 0.82
Altered peroxisome-proliferator activated receptors expression in human endometrial cancer. PPAR Res (2012) 0.82
Biological Rationale for the Use of PPARγ Agonists in Glioblastoma. Front Oncol (2014) 0.80
Proteomic analyses lead to a better understanding of celiac disease: focus on epitope recognition and autoantibodies. Dig Dis Sci (2010) 0.78
Expression Pattern of Fatty Acid Binding Proteins in Celiac Disease Enteropathy. Mediators Inflamm (2015) 0.77
Shared Genetic Factors Involved in Celiac Disease, Type 2 Diabetes and Anorexia Nervosa Suggest Common Molecular Pathways for Chronic Diseases. PLoS One (2016) 0.75
Innate immune system: the no man's land where discover new biomarkers for gluten-related-disorders. Gastroenterol Hepatol Bed Bench (2015) 0.75
Peroxisome proliferator-activated receptor-γ and thymic stromal lymphopoietin are involved in the pathophysiology of childhood coeliac disease. Virchows Arch (2014) 0.75
Celiac disease. N Engl J Med (2007) 10.98
Gluten, major histocompatibility complex, and the small intestine. A molecular and immunobiologic approach to the spectrum of gluten sensitivity ('celiac sprue'). Gastroenterology (1992) 10.44
Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev (1999) 9.94
Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15. Immunity (1998) 9.02
A genome-wide association study for celiac disease identifies risk variants in the region harboring IL2 and IL21. Nat Genet (2007) 8.50
Prevalence of celiac disease in at-risk and not-at-risk groups in the United States: a large multicenter study. Arch Intern Med (2003) 7.80
A systems biology approach for pathway level analysis. Genome Res (2007) 6.95
The histopathology of coeliac disease: time for a standardized report scheme for pathologists. Eur J Gastroenterol Hepatol (1999) 6.27
Coeliac disease in the year 2000: exploring the iceberg. Lancet (1994) 6.05
Roles of PPARs in health and disease. Nature (2000) 5.87
Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature (2000) 5.86
Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease. Nat Med (1998) 5.25
Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease. Immunity (2004) 4.36
Coeliac disease: dissecting a complex inflammatory disorder. Nat Rev Immunol (2002) 3.98
Association between innate response to gliadin and activation of pathogenic T cells in coeliac disease. Lancet (2003) 3.78
A direct role for NKG2D/MICA interaction in villous atrophy during celiac disease. Immunity (2004) 3.76
Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol (2002) 3.59
Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem (1999) 3.57
Refractory sprue, coeliac disease, and enteropathy-associated T-cell lymphoma. French Coeliac Disease Study Group. Lancet (2000) 3.47
Seroprevalence, correlates, and characteristics of undetected coeliac disease in England. Gut (2003) 3.30
Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol (2007) 3.23
Interleukin 15: a key to disrupted intraepithelial lymphocyte homeostasis and lymphomagenesis in celiac disease. Gastroenterology (2003) 3.05
Coeliac disease. Lancet (2009) 3.03
Gluten induces an intestinal cytokine response strongly dominated by interferon gamma in patients with celiac disease. Gastroenterology (1998) 2.69
Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol (2001) 2.66
An overview on biological mechanisms of PPARs. Pharmacol Res (2005) 2.43
The induction of antibody production by IL-6 is indirectly mediated by IL-21 produced by CD4+ T cells. J Exp Med (2009) 2.38
Raf kinase inhibitor protein interacts with NF-kappaB-inducing kinase and TAK1 and inhibits NF-kappaB activation. Mol Cell Biol (2001) 2.36
Regulatory role for a novel human thioredoxin peroxidase in NF-kappaB activation. J Biol Chem (1997) 2.01
DNA binding properties of peroxisome proliferator-activated receptor subtypes on various natural peroxisome proliferator response elements. Importance of the 5'-flanking region. J Biol Chem (1997) 2.00
PPARgamma as a new therapeutic target in inflammatory bowel diseases. Gut (2006) 1.99
Novel genetic risk markers for ulcerative colitis in the IL2/IL21 region are in epistasis with IL23R and suggest a common genetic background for ulcerative colitis and celiac disease. Am J Gastroenterol (2009) 1.96
Morphology of the mucosal lesion in gluten sensitivity. Baillieres Clin Gastroenterol (1995) 1.95
Tumor cell dependence on Ran-GTP-directed mitosis. Cancer Res (2008) 1.83
Coeliac disease: an update for pathologists. J Clin Pathol (2006) 1.76
Small bowel neoplasia in coeliac disease. Gut (2003) 1.73
Peroxisome proliferator-activated receptor alpha agonists as therapy for autoimmune disease. J Immunol (2004) 1.62
Regulation of cytokine expression by ligands of peroxisome proliferator activated receptors. J Immunol (2002) 1.44
Raf-1 kinase inhibitor protein: structure, function, regulation of cell signaling, and pivotal role in apoptosis. Adv Cancer Res (2004) 1.25
The metabonomic signature of celiac disease. J Proteome Res (2009) 1.24
Celiac disease: from gluten to autoimmunity. Autoimmun Rev (2008) 1.18
Effects of peroxisome proliferator-activated receptor-gamma agonists on central nervous system inflammation. J Neurosci Res (2003) 1.18
Clofibric acid, a peroxisome proliferator-activated receptor alpha ligand, inhibits growth of human ovarian cancer. Mol Cancer Ther (2007) 1.16
Role of skeletal muscle in thiazolidinedione insulin sensitizer (PPARgamma agonist) action. Endocrinology (1998) 1.16
Lymphocytic disorders of the gastrointestinal tract: a review for the practicing pathologist. Adv Anat Pathol (2009) 1.14
Intestinal T cell responses to gluten peptides are largely heterogeneous: implications for a peptide-based therapy in celiac disease. J Immunol (2009) 1.14
Peroxisome proliferator-activated receptor-gamma haploinsufficiency enhances B cell proliferative responses and exacerbates experimentally induced arthritis. J Clin Invest (2001) 1.12
Association of subepithelial deposition of activated complement and immunoglobulin G and M response to gluten in celiac disease. Gastroenterology (1992) 1.10
Duodenal intraepithelial lymphocytosis with normal villous architecture: common occurrence in H. pylori gastritis. Mod Pathol (2005) 1.08
Mechanisms of regulation of liver fatty acid-binding protein. Mol Cell Biochem (1993) 1.07
Nuclear factor kappa B is activated in small intestinal mucosa of celiac patients. J Mol Med (Berl) (2003) 1.03
NF-kappa B p65 transactivation domain is involved in the NF-kappa B-inducing kinase pathway. Biochem Biophys Res Commun (2003) 0.98
Proteomic analysis of cancer tissues: shedding light on carcinogenesis and possible biomarkers. Proteomics (2006) 0.98
Jejunal mucosal immunoglobulins and complement in untreated coeliac disease. J Pathol (1977) 0.96
Peroxisome proliferator-activated receptors and the metabolic syndrome. Physiol Behav (2007) 0.93
Genetic insights into the disease mechanisms of type II mixed cryoglobulinemia induced by hepatitis C virus. Dig Liver Dis (2007) 0.93
HCV-NS3 and IgG-Fc crossreactive IgM in patients with type II mixed cryoglobulinemia and B-cell clonal proliferations. Leukemia (2006) 0.92
TNF-related apoptosis-inducing ligand suppresses PRDX4 expression. FEBS Lett (2009) 0.92
The spectrum of coeliac disease in children. Baillieres Clin Gastroenterol (1997) 0.85
Increased protein expression of matrix metalloproteinases -1, -3, and -9 and TIMP-1 in patients with gluten-sensitive enteropathy. Dig Dis Sci (2006) 0.84
Comparative mitochondrial proteomic analysis of Rji cells exposed to adriamycin. Mol Med (2009) 0.81
HCV inhibits antigen processing and presentation and induces oxidative stress response in gastric mucosa. Proteomics Clin Appl (2008) 0.80
Comment re: Ran-GTP control of tumor cell mitosis. Cancer Res (2009) 0.79
Role of glucose and insulin in thiazolidinedione-induced alterations in hepatic gluconeogenesis. Eur J Pharmacol (2000) 0.79
Proteins specifically hyperexpressed in a coeliac disease patient with aberrant T cells. Clin Exp Immunol (2007) 0.78
Two-dimensional gel proteome reference map of human small intestine. Proteome Sci (2009) 0.76
p27(Kip1)-stathmin interaction influences sarcoma cell migration and invasion. Cancer Cell (2005) 2.65
[18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging (2006) 2.63
Local excision after preoperative chemoradiotherapy for rectal cancer: results of a multicenter phase II clinical trial. Dis Colon Rectum (2013) 2.52
Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. J Clin Oncol (2009) 2.40
Capsule endoscopy is useful and safe for small-bowel surveillance in familial adenomatous polyposis. Gastrointest Endosc (2008) 1.69
Stathmin activity influences sarcoma cell shape, motility, and metastatic potential. Mol Biol Cell (2008) 1.62
Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood (2002) 1.58
Clinical presentation and outcome of colorectal cancer in HIV-positive patients: a clinical case-control study. Onkologie (2009) 1.58
HCV-associated B cell clonalities in the liver do not carry the t(14;18) chromosomal translocation. Hepatology (2005) 1.57
Infliximab with low-dose methotrexate for prevention of postsurgical recurrence of ileocolonic Crohn disease. Arch Intern Med (2007) 1.51
Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients. Clin Cancer Res (2005) 1.47
A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis. Proc Natl Acad Sci U S A (2013) 1.44
Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma. Blood (2008) 1.43
The tumor suppressor functions of p27(kip1) include control of the mesenchymal/amoeboid transition. Mol Cell Biol (2009) 1.43
A predictive model identifies patients most likely to have inadequate bowel preparation for colonoscopy. Clin Gastroenterol Hepatol (2012) 1.42
Feasibility and diagnostic agreement in teledermatopathology using a virtual slide system. Hum Pathol (2007) 1.39
Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. Blood (2010) 1.37
Targeted intraoperative radiotherapy impairs the stimulation of breast cancer cell proliferation and invasion caused by surgical wounding. Clin Cancer Res (2008) 1.34
Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. Blood (2010) 1.27
Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome. Clin Cancer Res (2009) 1.22
Food groups and risk of non-Hodgkin lymphoma: a multicenter, case-control study in Italy. Int J Cancer (2006) 1.21
Antibody production and in vitro behavior of CD27-defined B-cell subsets: persistent hepatitis C virus infection changes the rules. J Virol (2006) 1.18
p27Kip1 expression inhibits glioblastoma growth, invasion, and tumor-induced neoangiogenesis. Mol Cancer Ther (2008) 1.16
Successful vaccination induces multifunctional memory T-cell precursors associated with early control of hepatitis C virus. Gastroenterology (2012) 1.12
Consensus guidelines on severe acute pancreatitis. Dig Liver Dis (2015) 1.12
Breast metastasis of primary colon cancer with micrometastasis in the axillary sentinel node: a metastasis that metastasized? Diagn Pathol (2011) 1.09
Long-term outcome of patients with complete pathologic response after neoadjuvant chemoradiation for cT3 rectal cancer: implications for local excision surgical strategies. Ann Surg Oncol (2011) 1.08
Clinical and dermoscopic features of porokeratosis of Mibelli. Arch Dermatol (2009) 1.08
Genetic characterization of p27(kip1) and stathmin in controlling cell proliferation in vivo. Cell Cycle (2014) 1.07
Risk factors for ovarian cancer histotypes. Eur J Cancer (2007) 1.06
Extrasalivary lymphoma development in Sjögren's syndrome: clonal evolution from parotid gland lymphoproliferation and role of local triggering. Arthritis Rheum (2003) 1.05
C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisation. Eur J Cancer (2009) 1.04
Identification of novel chimpanzee MHC class I and II alleles using an improved sequence-based typing strategy. Hum Immunol (2006) 1.04
Intrahepatic B cell clonal expansions and extrahepatic manifestations of chronic HCV infection. Eur J Immunol (2004) 1.02
Renal cell cancer and body size at different ages: an Italian multicenter case-control study. Am J Epidemiol (2007) 1.01
Reproductive, menstrual, and other hormone-related factors and risk of renal cell cancer. Int J Cancer (2008) 1.00
Interobserver agreement in describing video capsule endoscopy findings: a multicentre prospective study. Dig Liver Dis (2011) 0.99
Genome wide DNA-profiling of HIV-related B-cell lymphomas. Br J Haematol (2009) 0.97
Stathmin regulates mutant p53 stability and transcriptional activity in ovarian cancer. EMBO Mol Med (2013) 0.97
'Genetic profiling' and ovarian cancer therapy (review). Mol Med Rep (2011) 0.95
Recent prognostic factors in diffuse large B-cell lymphoma indicate NF-kappaB pathway as a target for new therapeutic strategies. Leuk Lymphoma (2008) 0.95
Hepatitis C virus, B-cell proliferation and lymphomas. Leuk Lymphoma (2002) 0.93
An effective multisource informed consent procedure for research and clinical practice: an observational study of patient understanding and awareness of their roles as research stakeholders in a cancer biobank. BMC Med Ethics (2013) 0.93
Differential proteomic analysis of hepatocellular carcinoma. Int J Oncol (2010) 0.92
Antibody V(h) repertoire differences between resolving and chronically evolving hepatitis C virus infections. PLoS One (2011) 0.91
Expression profiles in malignant fibrous histiocytomas: clues for differentiating 'spindle cell' and 'pleomorphic' subtypes. Eur J Cancer (2007) 0.91
Human immunodeficiency virus-associated precursor T-lymphoblastic leukemia/lymphoblastic lymphoma: report of a case and review of the literature. Hum Pathol (2009) 0.91
Primary nodal marginal zone B-cell lymphoma: clinical features and prognostic assessment of a rare disease. Br J Haematol (2007) 0.91
Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens. J Pharmacol Exp Ther (2013) 0.91
Negative pigment network and shiny white streaks: a dermoscopic-pathological correlation study. Am J Dermatopathol (2014) 0.91
Pegylated-interferon plus ribavirin for HCV-positive indolent non-Hodgkin lymphomas. Br J Haematol (2009) 0.90
Antibody responses to NY-ESO-1 in primary breast cancer identify a subtype target for immunotherapy. PLoS One (2011) 0.90
EGFR inhibition abrogates leiomyosarcoma cell chemoresistance through inactivation of survival pathways and impairment of CSC potential. PLoS One (2012) 0.90
A liquid chromatography-tandem mass spectrometry method for the simultaneous determination of exemestane and its metabolite 17-dihydroexemestane in human plasma. J Mass Spectrom (2009) 0.89
Somatostatin receptor subtypes 2 and 5 are associated with better survival in well-differentiated endocrine carcinomas. Neuroendocrinology (2008) 0.89
Fast liquid chromatography-tandem mass spectrometry method for routine assessment of irinotecan metabolic phenotype. Ther Drug Monit (2010) 0.89
Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment. Pharmacogenet Genomics (2013) 0.88
Revisiting the clinical value of 18F-FDG PET/CT in detection of recurrent epithelial ovarian carcinomas: correlation with histology, serum CA-125 assay, and conventional radiological modalities. Clin Nucl Med (2012) 0.88
Association of t(14;18) translocation with HCV infection in gastrointestinal MALT lymphomas. J Hepatol (2008) 0.88
Analysis of aberrant somatic hypermutation (SHM) in non-Hodgkin's lymphomas of patients with chronic HCV infection. J Pathol (2005) 0.88
Atypical Spitzoid melanocytic tumors: a morphological, mutational, and FISH analysis. J Am Acad Dermatol (2011) 0.88
Spontaneous T cell responses to Epstein-Barr virus-encoded BARF1 protein and derived peptides in patients with nasopharyngeal carcinoma: bases for improved immunotherapy. Int J Cancer (2008) 0.87
Retinoic acid inhibits the proliferative response induced by CD40 activation and interleukin-4 in mantle cell lymphoma. Cancer Res (2005) 0.87
Hepatitis C virus-induced oxidative stress and mitochondrial dysfunction: a focus on recent advances in proteomics. Proteomics Clin Appl (2010) 0.86
Role of genetic polymorphisms and mutations in colorectal cancer therapy (Review). Mol Med Rep (2010) 0.86
Undifferentiated nasopharyngeal carcinoma from a nonendemic area: protective role of HLA allele products presenting conserved EBV epitopes. Int J Cancer (2009) 0.86
Detection of bcl-2 rearrangement in mucosa-associated lymphoid tissue lymphomas from patients with hepatitis C virus infection. Haematologica (2004) 0.86
Incidental Epstein-Barr virus associated atypical lymphoid proliferation arising in a left atrial myxoma: a case of long survival without any postsurgical treatment and review of the literature. Cardiovasc Pathol (2012) 0.85
Pitfalls in the dermoscopic diagnosis of amelanotic melanoma. J Am Acad Dermatol (2010) 0.85
Gastrointestinal stromal tumors: report of an audit and review of the literature. Eur J Cancer Prev (2009) 0.85
Hepatitis C virus (HCV) I hepatitis C virus (HCV) infection and lymphoproliferative disorders. Front Biosci (2005) 0.84
Stathmin is dispensable for tumor onset in mice. PLoS One (2012) 0.84
BUBR1 expression in oral squamous cell carcinoma and its relationship to tumor stage and survival. Head Neck (2010) 0.84
Critical choices for modeling breast cancer in transgenic mouse models. J Cell Physiol (2012) 0.84
Androgen receptor serine 81 mediates Pin1 interaction and activity. Cell Cycle (2012) 0.84
A novel CDH1 germline missense mutation in a sporadic gastric cancer patient in north-east of Italy. Clin Exp Med (2012) 0.84
Pharmaco-metabolomics: an emerging "omics" tool for the personalization of anticancer treatments and identification of new valuable therapeutic targets. J Cell Physiol (2012) 0.84
IGKV3 proteins as candidate "off-the-shelf" vaccines for kappa-light chain-restricted B-cell non-Hodgkin lymphomas. Clin Cancer Res (2012) 0.83
Lack of HCV infection in malignant cells refutes the hypothesis of a direct transforming action of the virus in the pathogenesis of HCV-associated B-cell NHLs. Tumori (2002) 0.83
Diagnostic and therapeutic yield of single balloon enteroscopy in patients with suspected small-bowel disease: results of the Italian multicentre study. Dig Liver Dis (2012) 0.83
KIR/HLA combination associated with the risk of complications in celiac disease. Int J Biol Markers (2011) 0.83
BRAF and KIT somatic mutations are present in amelanotic melanoma. Melanoma Res (2013) 0.83
Highly selective salicylketoxime-based estrogen receptor β agonists display antiproliferative activities in a glioma model. J Med Chem (2015) 0.83
Rapid and sensitive analysis of vincristine in human plasma using on-line extraction combined with liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom (2008) 0.83
The versatile role of gliadin peptides in celiac disease. Clin Biochem (2012) 0.83
Elevated B cell-activating factor of the tumour necrosis factor family in coeliac disease. Scand J Gastroenterol (2007) 0.83
Interferon-based therapy for chronic hepatitis C: current and future perspectives. Hepat Mon (2010) 0.83